Allergic Rhinitis Clinical Trial
— DEVALPOOfficial title:
Prospective Multicenter Clinical Investigation Evaluating the Performance and Safety of Gilbert Laboratories' Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils
NCT number | NCT05494346 |
Other study ID # | DEVALPO |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 31, 2023 |
Est. completion date | November 30, 2024 |
The purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by Gilbert Laboratories. The study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.
Status | Recruiting |
Enrollment | 101 |
Est. completion date | November 30, 2024 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - 1. Patient = 12 years. - 2. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectious episodes such as allergic rhinitis. - 3. a. Informed adult patient who has given written consent prior to any study specific procedure. b. Informed minor patient who has given assent and whose legal guardians have given written consent prior to any study-specific procedure. - 4. Patient able to meet the study requirements for monitoring, spray use, and questionnaire completion. - 5. Patient affiliated to a social security scheme. Exclusion Criteria: - 1. Pregnant and/or breastfeeding woman - 2. Hypersensitivity to seawater and/or known allergies to any of the ingredients of the spray. - 3. Diseases causing narrowing of the airways (e.g. asthma, chronic obstructive pulmonary disease (COPD)) and/or respiratory insufficiency. - 4. Patients with chronic nasal obstruction. - 5. Patients on local and systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and local antiseptics. - 6. Concomitant use of other nasal sprays, essential oils for local nasal use, nasal creams or gels. - 7. Patients under guardianship, curatorship or safeguard of justice. |
Country | Name | City | State |
---|---|---|---|
France | Cabinet Médical Caen | Caen | |
France | Cabinet Médical Gainneville | Gainneville |
Lead Sponsor | Collaborator |
---|---|
Laboratoires Gilbert | EVAMED |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance of the Gilbert Laboratories pocket valve spray. | Proportion of patient presenting a change of the symptom "nasal obstruction" by at least 1 pt, in the SNOT22 Test (item 22), between Day 0 (at inclusion in the office before use of the spray) and Day 3 (in the evening after last daily use of the spray).
This item is scaled from 0 to 5, 5 being the worst value. |
From Day 0 to Day 3 | |
Secondary | Change of nasal obstruction between Day 0 and Day 3 | Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min between Day 0 (before use of the spray) and Day 3 (after use of the spray) (arm A).
[0 - 350 L/min] 350 L/min means a better outcome. |
From Day 0 to Day 3 | |
Secondary | Immediate change of nasale obstruction at D0 on first use (Arm A) | Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min from pre- to post-spray measurements at Day 0 (arm A).
[ 0 - 350 L/min] 350 L/min means a better outcome. |
At Day 0 | |
Secondary | Subjective feeling of reduced nasal obstruction on each day of use (arms A+B). | Proportion of patients with a reduction in the symptom "nasal obstruction" of at least 1pt, on SNOT22 (Sino-Nasal Outcome Test 22), and on each day of use (from Day 0 to Day 6) (arms A+B).
This item is scaled from 0 to 5, 5 being the worst value. |
From Day 0 to Day 6 | |
Secondary | Subjective feeling of nasal cavity cleansing (freshness) each day of use (arms A+B). | Proportion of patients who experienced nasal cavity cleansing (feeling of freshness), on Patient Questionnaire, and on each day of use (from Day 0 to Day 6) (arms A+B). | From Day 0 to Day 6 | |
Secondary | Subjective feeling of nasal secretion thinning on each day of use (arms A+B). | Proportion of patients with a change in the symptom "thick nasal discharge" of at least 1pt, on SNOT22, and on each day of use (Day 0 to Day 6) (arms A+B).
This item is scaled from 0 to 5, 5 being the worst value. |
From Day 0 to Day 6 | |
Secondary | Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use (arms A+B). | Proportion of patients who experienced relief of nasal (mucosal) irritation, on each day of use (Day 0 to Day 6) (arms A+B). | From Day 0 to Day 6 | |
Secondary | Subjective feeling of relief of nasal itching on each day of use (arms A+B). | Proportion of patients who experienced relief of nasal itching, on Patient Questionnaire, and on each day of use (Day 0 to Day 6) (arms A+B). | From Day 0 to Day 6 | |
Secondary | Speed of action at which the patient feels (subjectively) a decrease in nasal obstruction at D0 and D3 (arms A+B). | Proportion of patients with a change in immediate nasal obstruction after use of the spray, on Patient Questionnaire, at Day 0 and Day 3 (arms A+B). | At Day 0 and Day 3 | |
Secondary | Speed of action at which the patient feels (subjectively) a purification of his nasal cavities (sensation of freshness) at D0 and D3 (arms A+B). | Proportion of patients who experienced immediate nasal cleansing (feeling of freshness) after use of the spray at Day 0 and Day 3 (arms A+B). | At Day 0 and Day 3 | |
Secondary | Improvement in the patient's quality of life after 7 days of use (arms A+B). | Proportion of patients who experienced an improvement in quality of life, defined as an increase of at least 1pt on a scale of 0-10 between Day 0 and Day 6 (A+B arm).
10 mean a better value. |
From Day 0 to Day 6 | |
Secondary | Patient satisfaction with the medical device after 7 days of use (arm A+B). | Proportion of patients satisfied with the medical device, on a 4-point scale, at Day 6 (arm A+B).
The better value is "very satisfied" and the worst value is "very unsatisfied". |
At Day 6 | |
Secondary | Facility of use of the medical device after 7 days of use (arm A+B) | Proportion of patients who would recommend the medical device at Day 6 (arms A+B). | At Day 6 | |
Secondary | Evolution of the overall severity of symptoms (arm A+B). | Mean SNOT22 score on each day. Comparison of SNOT22 score at Day 3 versus Day 0 baseline (arms A+B).
[ 0 to 220 ] 0 is the better value. |
At Day 0 and Day 3 | |
Secondary | All adverse events reported by patients using the pocket valve spray after 7 days of use (arm A+B). | All adverse events reported by the patient during the study (arm A+B). | From Day 0 to Day 7 | |
Secondary | Sensations of tingling and transient irritation (arms A+B). | Proportion of patients with at least 1 adverse event between 1st and last use of the medical device among the following adverse events (arms A+B):
Tingling sensations Sensations of transient irritation |
From Day 0 to Day 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
Completed |
NCT01439815 -
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
|
Phase 4 |